English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Background/Aim. To evaluate the efficacy and safety of intravitreal injections of Bevacizumab before trabeculectomy with mitomycin C (MMC) for treatment of neovascular glaucoma (NVG). Methods. A prospective and open-label study, from May 2013 to December 2014, was conducted on consecutive NVG patients who underwent intravitreal injections of Bevacizumab and a primary trabeculectomy with MMC. All patients were followed-up at least for 12 months. Success was defined as an intraocular pressure (IOP) of ≤21 mm Hg with or without topical ocular hypotensive medication. Results. Fourteen eyes of 12 diabetic patients fulfilled the respective demands of the inclusion and exclusion criteria. The mean (standard deviation) follow-up period was 15.0 (2.0) months (range, 12 to 19 months). After one year of follow-up, 11 (78.6%) eyes had an IOP ≤ 21 mmHg. The mean IOP was significantly reduced from 42.4 (9.7) mmHg preoperatively to 18.4 (2.9) postoperatively, p<0.0001. Regarding surgical complications, hyphaema was observed in 3 (21.4%) eyes, macular edema in one eye (7.1%) after 6 months of trabeculectomy, and recurrence of neovascularization requiring intravitreal Bevacizumab injection in 2 eyes (14.2%) after 6 months. Conclusion. Preoperative intravitreal bevacizumab may be effective as adjunctive treatment for trabeculectomy with mitomycin-C for neovascular glaucoma patients.

Pre-trabeculectomy intravitreal injections of Bevacizumab for treating neovascular glaucoma in diabetic patients